<DOC>
	<DOCNO>NCT02691247</DOCNO>
	<brief_summary>This clinical trial explore safety effect autologous ex vivo expand polyclonal regulatory T-cells beta cell function patient , age 8 17 , recent onset T1DM . Other measure diabetes severity autoimmune response underlie T1DM also explore . Eligible subject receive single infusion CLBS03 ( high low dose ) placebo .</brief_summary>
	<brief_title>Safety Efficacy CLBS03 Adolescents With Recent Onset Type 1 Diabetes ( The Sanford Project T-Rex Study )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Male female age 8 17 year age Diagnosis T1DM within 100 day receipt study drug Positive least one islet cell autoantibody Peak MMTTstimulated Cpeptide level &gt; 0.2 pmol/mL ( screen visit ) Weight ≥30 kg Must agree use reliable acceptable method contraception duration participation Willing medically acceptable postpone live vaccine immunization one year infusion Written inform consent write assent Hemoglobin less low limit normal Leukocytes &lt; 3,000/μL ; neutrophil &lt; 1,500/μL ; lymphocyte &lt; 800/μL ; platelet &lt; 100,000/μL Regulatory Tcells present peripheral blood &lt; 20 cell per μL Current ongoing use noninsulin pharmaceutical ( may affect glycemic control ) Current anticipate use systemic corticosteroid immunomodulatory drug Recent serious bacterial , viral , fungal , opportunistic infection History malignancy serious uncontrolled cardiovascular , nervous system , pulmonary , renal , gastrointestinal disease Serologic evidence current past viral infection : human immunodeficiency virus ( HIV ) , Hepatitis B , Hepatitis C , human Tlymphotropic virus ( HTLV ) 1/2 Positive QuantiFERON® tuberculosis ( TB ) test , purify protein derivative ( PPD ) skin test , history tuberculosis , active TB infection Active infection EpsteinBarr Virus Cytomegalovirus Liver disease Pregnant breastfeed Vaccination live virus within 8 week receipt study drug Vaccination kill virus within 2 week receipt study drug Participation investigational drug study within 90 day prior screen Previously treat TReg base cell therapy History allergy gentamicin</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>T1DM</keyword>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>T regulatory cell</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Cell therapy</keyword>
	<keyword>T-Reg</keyword>
</DOC>